DOI: https://doi.org/10.22141/2307-1257.12.4.2023.424

EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis — the European Renal Association (ERA) — Immunonephrology Working Group (ERA-IWG) perspective

Eleni Frangou[1], Annette Bruchfeld[2, 3], Gema M. Fernandez-Juarez[4], Jürgen Floege[5], Dimitrios Goumenos[6], Sarah M. Moran[7], Stefanie Steiger[8], Kate I. Stevens[9], Kultigin Turkmen[10], Andreas Kronbichler[11]

[1]Department of Nephrology, Limassol General Hospital, Limassol, Cyprus; University of Nicosia Medical School, Nicosia, Cyprus

[2]Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

[3]Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden

[4]Department of Nephrology, Hospital Unversitatio La Paz, Madrid, Spain; Instituto de Investigacion la Paz, IDIPaZ, Spain

[5]Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany

[6]Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece

[7]Cork University Hospital, University College Cork, Cork, Ireland

[8]Renal Division, Department of Medicine IV, Ludwig-Maximilians-University Hospital Munich, Ludwig-Maximilians-University Munich, Germany

[9]Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK

[10]Division of Nephrology, Department of Internal Medicine, Necmettin Erbakan University, Konya, Turkey

[11]Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria



Figure 1. Specific considerations when evaluating the optimal currently approved add-on therapy of a patient with active lupus nephritis (LN) class III–V

Notes: BEL — belimumab; eGFR — estimated glomerular filtration rate; i.v. — intravenous; s.c. — subcutaneous; VCS — voclosporin.